Thrivent Financial for Lutherans lowered its position in Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,361,355 shares of the company’s stock after selling 101,730 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Twist Bioscience were worth $43,182,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Maxi Investments CY Ltd purchased a new position in Twist Bioscience in the fourth quarter valued at about $1,110,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Twist Bioscience by 11.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,668 shares of the company’s stock valued at $1,447,000 after purchasing an additional 4,704 shares in the last quarter. SBI Securities Co. Ltd. grew its stake in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares in the last quarter. Benjamin Edwards Inc. grew its stake in Twist Bioscience by 4.6% in the fourth quarter. Benjamin Edwards Inc. now owns 29,632 shares of the company’s stock valued at $940,000 after purchasing an additional 1,309 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its stake in Twist Bioscience by 2.1% in the fourth quarter. Conestoga Capital Advisors LLC now owns 56,785 shares of the company’s stock valued at $1,801,000 after purchasing an additional 1,185 shares in the last quarter.
Insider Buying and Selling at Twist Bioscience
In related news, Director Jan Johannessen sold 12,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total transaction of $673,440.00. Following the completion of the transaction, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. The trade was a 40.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total value of $470,000.00. Following the transaction, the director directly owned 21,084 shares of the company’s stock, valued at $990,948. This represents a 32.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 46,551 shares of company stock worth $2,566,533 in the last ninety days. 3.08% of the stock is owned by insiders.
Twist Bioscience Stock Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.66) EPS. As a group, equities research analysts forecast that Twist Bioscience Corporation will post -1.86 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Evercore boosted their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Leerink Partners upgraded Twist Bioscience from a “market perform” rating to an “outperform” rating and set a $70.00 price target for the company in a research note on Tuesday, May 5th. Barclays upped their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Robert W. Baird upped their price target on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Finally, Guggenheim upped their price target on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.57.
Read Our Latest Analysis on TWST
Twist Bioscience Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Stories
- Five stocks we like better than Twist Bioscience
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
